CiRA, Kyoto University and Astellas Phase 2 research agreement signed for iPS Cells
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
70+ CXOs from leading healthcare institutions across India attended the confluence at Mumbai
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
Mindset disagrees with and denies the allegations set forth from Reunion.
Time to combine innovation, access and technology to deliver positive patient outcomes
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
This artificial RNA ligase has higher thermostability than natural RNA ligase
Subscribe To Our Newsletter & Stay Updated